PRME

Over the past six months (approximately April to October 2026), Prime Medicine's stock (PRME) rose by 14.00%, despite a -37.46% decrease over the last year. Key events included an increase in stock price in October 2026 following the announcement of the first patient dosed in a global Phase 1/2 clinical trial for PM577a in Wilson Disease. In September 2026, the U.S. FDA cleared the Investigational New Drug (IND) application for PM647 in Alpha-1 Antitrypsin Deficiency, causing a 12-13% jump in PRME shares. In August 2026, the company reported a narrower second-quarter net loss of $42.1 million. The stock also saw a significant rise of +15.79% on July 8, 2026. PRME reached its all-time low of $1.11 in May 2025. The stock is characterized by high volatility, with a beta coefficient of 1.99, and its price is often influenced by clinical progress and regulatory milestones.